India
· Delayed Price · Currency is INR Jubilant Pharmova Statistics
Total Valuation
Jubilant Pharmova has a market cap or net worth of INR 180.71 billion. The enterprise value is 200.60 billion.
| Market Cap | 180.71B |
| Enterprise Value | 200.60B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Aug 2, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 55.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.59, with an EV/FCF ratio of -73.11.
| EV / Earnings | 33.82 |
| EV / Sales | 2.90 |
| EV / EBITDA | 19.59 |
| EV / EBIT | 28.65 |
| EV / FCF | -73.11 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.80 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 3.14 |
| Debt / FCF | -11.23 |
| Interest Coverage | 2.52 |
Financial Efficiency
Return on equity (ROE) is 10.40% and return on invested capital (ROIC) is 4.54%.
| Return on Equity (ROE) | 10.40% |
| Return on Assets (ROA) | 3.52% |
| Return on Capital (ROIC) | 4.54% |
| Revenue Per Employee | 12.82M |
| Profits Per Employee | 1.10M |
| Employee Count | 5,399 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.92 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +165.08% in the last 52 weeks. The beta is 1.59, so Jubilant Pharmova's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +165.08% |
| 50-Day Moving Average | 1,168.23 |
| 200-Day Moving Average | 823.49 |
| Relative Strength Index (RSI) | 45.48 |
| Average Volume (20 Days) | 317,867 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jubilant Pharmova had revenue of INR 69.20 billion and earned 5.93 billion in profits. Earnings per share was 37.33.
| Revenue | 69.20B |
| Gross Profit | 45.29B |
| Operating Income | 6.57B |
| Pretax Income | 6.91B |
| Net Income | 5.93B |
| EBITDA | 9.23B |
| EBIT | 6.57B |
| Earnings Per Share (EPS) | 37.33 |
Balance Sheet
The company has 10.77 billion in cash and 30.80 billion in debt, giving a net cash position of -20.03 billion.
| Cash & Cash Equivalents | 10.77B |
| Total Debt | 30.80B |
| Net Cash | -20.03B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 59.27B |
| Book Value Per Share | 373.88 |
| Working Capital | 15.55B |
Cash Flow
In the last 12 months, operating cash flow was 7.68 billion and capital expenditures -10.42 billion, giving a free cash flow of -2.74 billion.
| Operating Cash Flow | 7.68B |
| Capital Expenditures | -10.42B |
| Free Cash Flow | -2.74B |
| FCF Per Share | n/a |
Margins
Gross margin is 65.46%, with operating and profit margins of 9.49% and 8.57%.
| Gross Margin | 65.46% |
| Operating Margin | 9.49% |
| Pretax Margin | 9.99% |
| Profit Margin | 8.57% |
| EBITDA Margin | 13.34% |
| EBIT Margin | 9.49% |
| FCF Margin | -3.97% |
Dividends & Yields
Jubilant Pharmova does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.42% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.03% |
| Earnings Yield | 3.28% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.
| Last Split Date | Mar 17, 2006 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |